Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

673 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.
Wattad M, Weber D, Döhner K, Krauter J, Gaidzik VI, Paschka P, Heuser M, Thol F, Kindler T, Lübbert M, Salih HR, Kündgen A, Horst HA, Brossart P, Götze K, Nachbaur D, Köhne CH, Ringhoffer M, Wulf G, Held G, Salwender H, Benner A, Ganser A, Döhner H, Schlenk RF. Wattad M, et al. Among authors: dohner k, dohner h. Leukemia. 2017 Jun;31(6):1306-1313. doi: 10.1038/leu.2017.23. Epub 2017 Jan 19. Leukemia. 2017. PMID: 28138160
Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.
Schlenk RF, Hartmann F, Hensel M, Jung W, Weber-Nordt R, Gabler A, Haas R, Ho AD, Trümper L, Döhner H. Schlenk RF, et al. Among authors: dohner h. Leukemia. 2002 Apr;16(4):581-6. doi: 10.1038/sj.leu.2402423. Leukemia. 2002. PMID: 11960336 Clinical Trial.
Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial.
Schlenk RF, Benner A, Hartmann F, del Valle F, Weber C, Pralle H, Fischer JT, Gunzer U, Pezzutto A, Weber W, Grimminger W, Preiss J, Hensel M, Fröhling S, Döhner K, Haas R, Döhner H; AML Study Group Ulm (AMLSG ULM). Schlenk RF, et al. Among authors: dohner k, dohner h. Leukemia. 2003 Aug;17(8):1521-8. doi: 10.1038/sj.leu.2403009. Leukemia. 2003. PMID: 12886238 Clinical Trial.
Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia.
Schlenk RF, Fröhling S, Hartmann F, Fischer JT, Glasmacher A, del Valle F, Grimminger W, Götze K, Waterhouse C, Schoch R, Pralle H, Mergenthaler HG, Hensel M, Koller E, Kirchen H, Preiss J, Salwender H, Biedermann HG, Kremers S, Griesinger F, Benner A, Addamo B, Döhner K, Haas R, Döhner H; AML Study Group Ulm. Schlenk RF, et al. Among authors: dohner k, dohner h. Leukemia. 2004 Nov;18(11):1798-803. doi: 10.1038/sj.leu.2403528. Leukemia. 2004. PMID: 15385923 Clinical Trial.
High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia.
Schlenk RF, Germing U, Hartmann F, Glasmacher A, Fischer JT, del Valle y Fuentes F, Götze K, Pralle H, Nerl C, Salwender H, Grimminger W, Petzer A, Hensel M, Benner A, Zick L, Döhner K, Fröhling S, Döhner H; AML Study Group (AMLSG). Schlenk RF, et al. Among authors: dohner k, dohner h. Leukemia. 2005 Jun;19(6):978-83. doi: 10.1038/sj.leu.2403766. Leukemia. 2005. PMID: 15843821 Clinical Trial.
Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment Trial.
Schlenk RF, Fröhling S, Hartmann F, Fischer JT, Glasmacher A, Del Valle F, Götze K, Nerl C, Schoch R, Pralle H, Mergenthaler HG, Hensel M, Koller E, Kirchen H, Matzdorff A, Salwender H, Biedermann HG, Kremers S, Haase D, Benner A, Döhner K, Döhner H. Schlenk RF, et al. Among authors: dohner k, dohner h. Leukemia. 2006 Apr;20(4):748-50. doi: 10.1038/sj.leu.2404122. Leukemia. 2006. PMID: 16437135 Clinical Trial. No abstract available.
673 results